Skip to main content
Healthcare

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Feed excerpt — reported by STAT News

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.